WOONSOCKET, R.I., Feb. 21, 2024 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced that Executive Vice President and Chief Financial Officer Tom Cowhey will participate in a fireside chat with investors at the 45nd Annual Raymond James Institutional Investors Conference on March 5, 2024, at approximately 9:50 a.m. eastern time.
An audio webcast of the event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website at investors.cvshealth.com where it will be archived for a period of one year.
CVS Health® is the leading health solutions company, broadening access to care for millions of people nationwide. We improve the health of communities across America through our local presence, digital channels and with over 300,000 dedicated colleagues – including more than 40,000 physicians, pharmacists, nurses, and nurse practitioners. We support individuals with their health – whether that's managing health conditions, staying compliant with their medications or accessing affordable health services in the most convenient ways. Our goal is to create seamless connections across the health care system, simplifying the experience and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Follow @CVSHealth on social media.
Last Trade: | US$66.88 |
Daily Change: | -1.67 -2.44 |
Daily Volume: | 15,611,840 |
Market Cap: | US$84.270B |
February 17, 2025 February 12, 2025 November 19, 2024 November 18, 2024 November 06, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load